TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06653192

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-expandable metallic stent (SEMS)
Description: Self-expandable metallic stent (SEMS) deployment:~Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~Size: 10x40mm or 10x60mm or 10x80mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)
Description: Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm. DPPS size: 7Fr x 3-7cm.
Study: NCT06060574

Intervention type: DEVICE
Intervention: Platelet rich fibrin device
Description: Within the scope of the study, a total of 2 tubes of venous blood samples will be obtained from the forearm region (antecubital vein) of each individual by the clinical staff specialist nurse of the Department of Periodontology. PRF samples will be created using appropriate equipment and devices from blood samples obtained from each individual. In the study, 10 ml glass-coated plastic tubes will be used. Apart from this, 5 mL of blood taken will be used for complete blood count and evaluation of hormones on the relevant day.~PRF Preparation: In all age groups, PRF will be prepared by centrifugation with 700xg (=2700 rpm, Intra-Spin L-PRF device) for 12 minutes.

Intervention type: DEVICE
Intervention: Platelet rich fibrin device
Description: Within the scope of the study, a total of 2 tubes of venous blood samples will be obtained from the forearm region (antecubital vein) of each individual by the clinical staff specialist nurse of the Department of Periodontology. PRF samples will be created using appropriate equipment and devices from blood samples obtained from each individual. In the study, 10 ml glass-coated plastic tubes will be used. Apart from this, 5 mL of blood taken will be used for complete blood count and evaluation of hormones on the relevant day.~PRF Preparation: In all age groups, PRF will be prepared by centrifugation with 700xg (=2700 rpm, Intra-Spin L-PRF device) for 12 minutes.
Study: NCT05109169

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FINGER 2.0 multidomain lifestyle-based intervention
Description: Multimodal lifestyle-based precision prevention intervention, including:~* Optimized FINGER multidomain lifestyle intervention (diet, physical activity, cognitive training and cardiovascular/metabolic risk monitoring and social interaction)~* Metformin (Glucophage® XR)
Study: NCT06060574

Intervention type: DEVICE
Intervention: Platelet rich fibrin device
Description: Within the scope of the study, a total of 2 tubes of venous blood samples will be obtained from the forearm region (antecubital vein) of each individual by the clinical staff specialist nurse of the Department of Periodontology. PRF samples will be created using appropriate equipment and devices from blood samples obtained from each individual. In the study, 10 ml glass-coated plastic tubes will be used. Apart from this, 5 mL of blood taken will be used for complete blood count and evaluation of hormones on the relevant day.~PRF Preparation: In all age groups, PRF will be prepared by centrifugation with 700xg (=2700 rpm, Intra-Spin L-PRF device) for 12 minutes.
Study: NCT05109169

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Self-guided multidomain lifestyle intervention
Description: Participants build their own healthy lifestyle program based on standard healthy lifestyle advice on diet, physical activity, cognitive training and cardiovascular/metabolic risk
Study: NCT06540144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozanolixizumab
Description: rozanolixizumab solution for injection
Study: NCT05198791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets
Description: Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
Study: NCT04972318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure titration with driving pressure control
Description: Positive end-expiratory pressure will be tailored during a decremental maneuver (without a formal alveolar recruitment maneuver). The best positive end-expiratory pressure will be defined as the one associated with the higher respiratory system compliance, up to 20 cmH2O. Plateau pressure limit will be 30 cmH2O. If driving pressure remains elevated after optimal PEEP setting, tidal volume will be reduced to keep driving pressure below 14 cmH2O.
Study: NCT05198791

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stratification and standard care
Description: Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
Study: NCT06651892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enema Phosphates Sodium
Description: oral diluted phosphate enema containing as a repletion strategy to replace phosphate in critically ill patients with acute hypophosphatemia.
Study: NCT05093699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Butterfly iQ+ ultrasound probe
Description: Diagnostic ultrasound probe on-market (FDA approved) capable of dual-plane viewing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound probe
Description: Standard single-view ultrasound probe
Study: NCT06651892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycophos Injectable Product
Description: intravenous sodium glycerophosphate as the standard of care or active control
Study: NCT04792112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision support tool
Description: Decision support tool for late preterm antenatal corticosteroids
Study: NCT05126927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-SNA006
Description: A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
Study: NCT06609252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast milk odour
Description: On the day of the study, the mothers of the babies will be contacted and fresh breast milk will be obtained from the mother of each baby. In the study, a sterile sponge will be used to smell the breast milk to the baby. Breast milk will be taken as 2 ml, dripped onto a sterile sponge and held 10 cm away from the baby's nose and sniffed 2 minutes before the examination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother voice
Description: Mothers of premature babies in the mother voice group will be given a voice recorder on the day of the study and will be encouraged to express their feelings and thoughts and say what they want to say to their babies and will be asked to talk to their babies as they wish. The mother's voice, which is recorded 2 minutes before the procedure, will be placed approximately 30 cm away from the baby's ear and a loudspeaker will be placed at the foot end so that the baby can listen to the sound.
Study: NCT06611085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold application group
Description: The index finger of the child will be used in the cold application group. In this group, cold application will be performed by placing the index finger of the designated hand on a 10 x 10 cm ice pack for 30 seconds and then removing the ice pack immediately.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration group
Description: The middle finger of the child will be used in the vibration group. In this group, vibration was applied by targeting the tip of the middle finger area using a vibrator device measuring 2x1x3 cm. The insertion of the needle will coincide with the application of the vibration stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration and ice group
Description: In the vibration and ice group, cold and vibration stimulation will be applied to the child simultaneously. The ring finger of the designated hand was placed on a 10x10 cm ice pack for 30 seconds and subjected to cold application. Simultaneously, vibration stimulation will be applied to the tip of the middle finger area using a vibrator device with dimensions of 3x1 cm and 2x1 cm. After 30 seconds, the ice bag will be removed and the lancet pen will be adjusted for drilling from the fingertip while vibration stimulation continues.
Study: NCT06096909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafolecimab
Description: The PCSK9 mAb in this study is defined as Tafolecimab 150mg q2w subcutaneously. For the two groups of lipid-lowering regimens, the lipid-lowering drug regimens other than PCSK9 mAb were maintained throughout the study as much as possible in accordance with the guidelines related to blood lipids, provided that no serious safety problems occurred.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholesterol Absorption Inhibitor
Description: Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.
Study: NCT05075551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL23 is in the sacral region, in the second posterior sacral foramen; BL54 is in the fourth posterior sacral foramen, 3 cun beside the median sacral crest; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.These volunteers will receive relatively shallow needling at bilateral sham SP6, BL54, BL23 and BL35. This treatment gets involved in the same duration and frequency of sessions, but the treatment was delivered superficially at non-acupuncture points 10 mm to the lateral of corresponding acupuncture and not above a meridian line (10mm to SP6, BL54, BL23 and BL35).The same equipment of fMRI scanner will be used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI scan
Description: Both two group will get fMRI scan week 0 (before treatment), week 12 (after treatment) and week 36 (following up). The resting-state fMRI data will be obtained by using a 3.0T GE MR 750 MRI scanner with an eight-channel phase array head coil at the Huashan Hospital, Shanghai. The high resolution T1-weighted magnetic resonance images will be collected by a three-dimensional fast spoiled gradient-echo dual-echo sequence \[repetition time (TR) = 8100 ms; echo time (TE) = 3.1 ms; FA = 8 deg; matrix=256 × 256; field of view (FOV)=25.6× 25.6 cm2; slice thickness=1 mm; no gap and 156 slices\]. The whole resting state fMRI data will be acquired by using a gradient-recalled echo-planar imaging pulse sequence (TR/TE = 2,000/30 ms; FA = 90°; acquisition matrix = 64×64; FOV = 22×22 cm2; slice thickness= 4 mm; 43 slices and total 240 time points; no gap).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: fMRI scan
Description: Both two group will get fMRI scan week 0 (before treatment), week 12 (after treatment) and week 36 (following up). The resting-state fMRI data will be obtained by using a 3.0T GE MR 750 MRI scanner with an eight-channel phase array head coil at the Huashan Hospital, Shanghai. The high resolution T1-weighted magnetic resonance images will be collected by a three-dimensional fast spoiled gradient-echo dual-echo sequence \[repetition time (TR) = 8100 ms; echo time (TE) = 3.1 ms; FA = 8 deg; matrix=256 × 256; field of view (FOV)=25.6× 25.6 cm2; slice thickness=1 mm; no gap and 156 slices\]. The whole resting state fMRI data will be acquired by using a gradient-recalled echo-planar imaging pulse sequence (TR/TE = 2,000/30 ms; FA = 90°; acquisition matrix = 64×64; FOV = 22×22 cm2; slice thickness= 4 mm; 43 slices and total 240 time points; no gap).
Study: NCT04895046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 300 mg taken orally (all cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: 500 mg (cycles 1-4) intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: 1000 mg (cycle 5+) intravenously
Study: NCT04983589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine HCl
Description: Pilocarpine HCl ophthalmic solution 1.25% ocular drops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Oxymetazoline HCl and pilocarpine HCl placebo ocular drops.
Study: NCT05635682

Intervention type: OTHER
Intervention: Observational and anthropometric assesments
Description: Plantar sensation, foot reaction time, head and trunk proprioceptions, posture, balance and gait assesments

Intervention type: OTHER
Intervention: Observational and anthropometric assesments
Description: Plantar sensation, foot reaction time, head and trunk proprioceptions, posture, balance and gait assesments
Study: NCT06649890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xperience™ Advanced Surgical Irrigation
Description: Xperience™ solution will be applied twice during reconstruction procedures: first after achieving hemostasis and second just before implant introduction. The solution will be warmed to body temperature before use. Both tissue expanders/implants and mastectomy pockets will be soaked with Xperience™, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of Xperience™ will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout, and no rinsing will occur post-irrigation. Surgical site closure will follow standard procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilute Povidone-Iodine
Description: 5% dilute povidone-iodine solution will be prepared by mixing povidone-iodine solution and normal saline at the appropriate ratio. Both tissue expanders/implants and mastectomy pockets will be soaked with dilute povidone-iodine, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of dilute povidone-iodine will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout. Surgeon discretion will determine rinsing after irrigation. Surgical site closure will follow standard procedures.
Study: NCT04699656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plazomicin Injection
Description: single dose of plazomicin
Study: NCT05100615

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: applying the graft inside bony defect after surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: applying the graft inside bony defect after surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: applying the graft inside bony defect after surgery
Study: NCT05455476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Loneliness
Description: CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth more centrally focused addressing factors contributing to loneliness and social isolation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Chronic Pain
Description: CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth broadly focused on increasing quality of life despite being in pain.
Study: NCT04972318

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ARDSNet ventilatory strategy
Description: Positive end-expiratory pressure will be set according to fixed inspired oxygen fraction values.
Study: NCT05845866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Body Project
Description: The Body Project, an evidence-based body image intervention developed for young women at risk for eating pathology, was adapted for use among adult women with high weight and shape concern and high body weight who want to lose weight.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facts about obesity, myths about weight loss
Description: This intervention is designed to help individuals prepare for weight loss and is focused on facts about obesity, myths about weight loss, and the importance of a varied diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention for weight loss
Description: This 24-week behavioral weight management program is based on the Look AHEAD and Diabetes Prevention Program manuals. It is designed to facilitate 7-10% weight loss of initial body weight through dietary and physical activity changes with use of behavioral strategies to support lifestyle changes over time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for weight loss
Description: This 24-week behavioral weight management program is based on the Look AHEAD and Diabetes Prevention Program manuals. It is designed to facilitate 7-10% weight loss of initial body weight through dietary and physical activity changes with use of behavioral strategies to support lifestyle changes over time.
Study: NCT05859594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
Study: NCT06411873

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Composition of formula per 100 mL : energy (100 kcal), protein (3 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 12%, osmolarity (310 mOsm/L), renal solute load/RSL (27.5 mOsm/100 kcal)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Composition of formula per 100 mL : energy (105.5 kcal), protein (4.35 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 16.5%, osmolarity (333.5 mOsm/L), renal solute load/RSL (27.7 mOsm/100 kcal)
Study: NCT06418594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab: 1200mg, ivgtt, administered on the first day of each cycle, with a cycle of 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib: 250 mg, oral, once daily, continuous use, with a cycle of 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide: 50mg/day, oral, administered on days 1-14 of each cycle, with a cycle of 21 days
Study: NCT06360393

Intervention type: DEVICE
Intervention: Smart spacer
Description: Participants' inhalation medication adherence and inhalation technique will be monitored using a smart spacer. Their usual medication regime will be continued and they will not receive information about their adherence or inhalation technique measured by the spacer during the follow-up year (except for any interventions that will be done in standard care).
Study: NCT04947696

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling preoperatively and sequentially up to 30 days post op
Study: NCT05548946

Intervention type: OTHER
Group type: OTHER
Intervention: PID-5-BF+M and LPFS-BF 2.0 (self-report questionnaires)
Description: All participants will be asked to fill in the PID-5-BF+M and the LPFS-BF 2.0 to examine personality disorders as defined by the AMPD and ICD-11.~PID-5-BF+M consists of 36 self-report items. It has 18 facet scales and 6 domain scales (Anankastia, Negative Affectivity, Antagonism, Disinhibition, Psychoticism and Detachment).~The LPFS-BF 2.0 has 12 items, measuring 4 domains of personality functioning (identity, intimacy, self-direction and empathy).

Intervention type: OTHER
Group type: OTHER
Intervention: PID-5-BF+M and LPFS-BF 2.0 (self-report questionnaires)
Description: All participants will be asked to fill in the PID-5-BF+M and the LPFS-BF 2.0 to examine personality disorders as defined by the AMPD and ICD-11.~PID-5-BF+M consists of 36 self-report items. It has 18 facet scales and 6 domain scales (Anankastia, Negative Affectivity, Antagonism, Disinhibition, Psychoticism and Detachment).~The LPFS-BF 2.0 has 12 items, measuring 4 domains of personality functioning (identity, intimacy, self-direction and empathy).
Study: NCT06344676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive
Description: Tree 10 minutes individual sessions per week involving memory, attention and executive functions tasks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobility
Description: Two 30 minutes group session per week involving physical activity assisted by a social robot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social
Description: One 60 minutes group session per month assisted by a social robot that facilitates talking about costumes and traditions.